Ocumension Therapeutics

As of December 31, 2025, Ocumension Therapeutics carries a market capitalization of 627.33M, placing it among publicly traded companies globally. Its enterprise value stands at 583.51M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Ocumension Therapeutics's next confirmed earnings release is scheduled for March 19, 2027.

As of December 31, 2025, Ocumension Therapeutics has 803.92M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Ocumension Therapeutics maintains a current ratio of 3.70, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 23, 2026, Ocumension Therapeutics's stock has declined approximately 36.84% over the past 52 weeks. The 50-day moving average sits at 0.58, while the 200-day moving average is 0.66.

As of December 31, 2025, Ocumension Therapeutics holds 66.64M in cash and equivalents against 22.83M in total debt, resulting in a net debt position of -26.69M. Total book value stands at 448.00M, with working capital of 84.50M providing operational flexibility.